Denver, CONCT07286032Now EnrollingIRB Ready

Patients With Chemotherapy-Induced Thrombocytopenia Clinical Trial in Denver, CO

Access cutting-edge patients with chemotherapy-induced thrombocytopenia treatment through this clinical trial at a research site in Denver. Study-provided care at no cost to qualified participants.

Sponsored by Jiangsu HengRui Medicine Co., Ltd.

Quick Self-Assessment

See if you qualify for this Denver location

Preparing your pre-screening questions…

Expert Care in Denver

Access patients with chemotherapy-induced thrombocytopenia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related patients with chemotherapy-induced thrombocytopenia treatment provided free

Apply for This Denver Location

Check if you qualify for this patients with chemotherapy-induced thrombocytopenia clinical trial in Denver, CO

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Denver

    Convenient for CO residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Denver site if eligible
  4. 4Begin participation

About This Patients With Chemotherapy-Induced Thrombocytopenia Study in Denver

The study is being conducted to evaluate the efficacy, and safety of of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia.

Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Who Can Participate

Inclusion Criteria

Male or female gender, age ≥18 years at screening.
Histologically or cytologically confirmed solid tumor (e.g., non-small-cell lung carcinoma \[NSCLC\], breast, ovarian, bladder, pancreatic, gastrointestinal, or colon/colorectal cancer).
Receiving platinum- and/or gemcitabine-containing chemotherapy regimens on 21-day treatment cycles.
Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2.
Life expectancy ≥6 months.
Signed ICF for voluntary participation in the study and good compliance.

Exclusion Criteria

Hematopoietic diseases other than CIT (e.g., primary immune thrombocytopenia).
Hematologic malignancies.
Thrombocytopenia caused by reasons other than chemotherapy, including but not limited to chronic liver disease, hypersplenism, infection, and hemorrhage, within 6 months prior to Study Day 1.
Untreated brain metastases; or with leptomeningeal metastasis.
Conditions that require emergent treatment (e.g., superior vena cava syndrome, spinal cord compression).
Severe cardiovascular disorders or interventions within 6 months
Have arterial/venous thrombosis within 6 months
Known bleeding disorders, platelet dysfunction
Severe haemorrhage during screening
Acute or uncontrolled hepatitis B\&C infection
Human immunodeficiency virus (HIV) infection.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Denver?

Yes, this clinical trial (NCT07286032) has an active research site in Denver, CO that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Patients With Chemotherapy-Induced Thrombocytopenia Treatment Options in Denver, CO

If you're searching for patients with chemotherapy-induced thrombocytopenia treatment options in Denver, CO, this clinical trial (NCT07286032) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Denver research site is actively enrolling participants for this clinical trial. You'll receive care from experienced patients with chemotherapy-induced thrombocytopenia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all patients with chemotherapy-induced thrombocytopenia clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Embolism Trials in Denver, CO

See all pulmonary embolism clinical trials recruiting in Denver — not just this study.

Browse Pulmonary Embolism Trials in Denver →

Browse More Trials by Condition

Pulmonary Embolism TrialsRheumatoid Arthritis TrialsUlcerative Colitis TrialsErectile Dysfunction TrialsThrombocytopenia TrialsAll Conditions →

Ready to Join in Denver?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Denver, CO